

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody Reagent
901-360VP-060223

BIOCARE
M E D I C A L

| Available Product Formats | | | | |
|---------------------------|------------------|-------------|--------------|---------|
| Format | Catalog Number | Description | Dilution | Diluent |
| UltraLine – For BenchMark | VP 360DSK G, G25 | 6.0, 25mL | Ready-to-use | N/A |

Intended Use:

For In Vitro Diagnostic Use

CK5/14 + p63 + CK7/18 is intended for laboratory use in the qualitative identification of keratins CK5, CK7, CK14, and CK18, and p63 by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:

CK5/14 + p63 + CK7/18 is comprised of mouse monoclonal anti-CK5, anti-CK14, and anti-p63 antibodies and rabbit monoclonal anti-CK7 and anti-CK18 antibodies. CK5 and CK14 are high molecular weight keratins expressed in the cytoplasm of basal cells and myoepithelium of breast tissue (1-4). p63 is a transcription factor present in the nuclei of myoepithelial cells (2,4). In contrast, CK7 and CK18 are low molecular weight cytokeratins primarily expressed in luminal cells of the breast (1-3).

CK5, CK14, p63, CK7 and CK18 have routinely been used as IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-5). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-2,6-10). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma *in situ* (LG-DCIS) were negative for the basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-8). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (11-13).

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase inter-observer agreement amongst pathologists, compared to H&E alone (14).

Principle of Procedure:

A sequential double stain is used for the simultaneous detection of two different antigens within one tissue section. A primary antibody is applied to the tissue, followed by a horseradish peroxidase (HRP) detection system. A denaturing step is required to eliminate cross-reactivity from the application of the second detection system. A second primary antibody is then applied, followed by an alkaline phosphatase (AP) detection system. Visualization of antigens is achieved with DAB and Red chromogens.

Reagent Provided:

CK5/14 + p63 + CK7/18 (VP360DSK) is provided as follows:

1. Prediluted antibody cocktail of anti-CK5, anti-CK14 and anti-p63 antibodies (VP401G), in buffer with carrier protein and preservative.

| Antibody | anti-CK5 | anti-CK14 | anti-p63 |
|-----------------------|------------------|------------------|------------------|
| Clone | XM26 | LL002 | 4A4 |
| Source | Mouse monoclonal | Mouse monoclonal | Mouse monoclonal |
| Isotype | IgG1/kappa | IgG3 | IgG2a/kappa |
| Epitope/ Antigen | CK5 | CK14 | p63 |
| Cellular Localization | Cytoplasmic | Cytoplasmic | Nuclear |
| Staining | Brown (DAB) | Brown (DAB) | Brown (DAB) |

2. Prediluted antibody cocktail of anti-CK7, anti-CK18 antibodies (VP402G), in buffer with carrier protein and preservative.

| Antibody | anti-CK7 | anti-CK18 |
|-----------------------|-------------------|-------------------|
| Clone | BC1 | EP30* |
| Source | Rabbit monoclonal | Rabbit monoclonal |
| Isotype | IgG | IgG |
| Epitope/ Antigen | CK7 | CK18 |
| Cellular Localization | Cytoplasmic | Cytoplasmic |
| Staining | Red | Red |

*Previously known as E431-1

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date.

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Species Reactivity: Human

Positive Tissue Control: Breast carcinoma

Protocol Recommendations (Ventana BenchMark XT / ULTRA):

Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

Template: IHC DS uDAB-uRed Template

Pretreatment Protocol: CC1 Standard

Primary Antibody (VP401): 32 minutes, 37°C

- ultraWash -

Primary Antibody (VP402): 32 minutes, 37°C

Detection: ultraView DAB and AP Detections

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody Reagent
901-360VP-060223

BIOCARE
M E D I C A L

Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (15)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (16)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at <http://biocare.net>.

Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

References:

1. Hicks DG. Immunohistochemistry in the Diagnostic Evaluation of Breast Lesions. *Appl Immunohistochem Mol Morph*. 2011; 19:501-5.
2. Moriya T, *et al*. New trends of immunohistochemistry for making differential diagnosis of breast lesions. *Med Mol Morphol*. 2006; 39:8-13.
3. Yeh IT, Mies C. Application of Immunohistochemistry to Breast Lesions. *Arch Pathol Lab Med*. 2008; 132:349-57.
4. Lerwill MF. Current Practical Applications of Diagnostic Immunohistochemistry in Breast Pathology. *Am J Surg Pathol*. 2004; 28:1076-91.
5. Moriya T, *et al*. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions. *Breast Cancer*. 2009; 16:173-8.

References Cont'd:

6. Otterbach F, *et al*. Cytokeratin 5/6 immunohistochemistry assists in differential diagnosis of atypical proliferations of the breast. *Histopathology*. 2000; 37:232-40.
7. Lacroix-Triki M, *et al*. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. *Virchows Arch*. 2003; 442:548-54.
8. Boecker W, *et al*. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. *J Pathol*. 2002; 198:458-67.
9. Koo JS, *et al*. Comparison of Immunohistochemical Staining in Breast Papillary Neoplasm of Cytokeratin 5/6 and p63 in core Needle Biopsies and Surgical Excisions. *Appl Immunohistochem Mol Morph*. 2012; 20:108-15.
10. Ichihara S, *et al*. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. *Path Int*. 2007; 57:126-32.
11. Livasy CA, *et al*. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol*. 2006; 19:264-71.
12. Laakso M, *et al*. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. *Mod Pathol*. 2005; 18:1321-8.
13. Bhargava R, *et al*. CK5 is More Sensitive than CK5/6 in Identifying the "Basallike" Phenotype of Breast Carcinoma. *Am J Clin Pathol*. 2008; 130:724-30.
14. Jain RK, *et al*. Atypical ductal hyperplasia: interobserver and intraobserver variability. *Mod Pathol*. 2011; 24:917-23.
15. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
16. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

UltraLine antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare's antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Produced using Abcam's RabMab® technology. RabMAB® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.